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a  b  s  t  r  a  c  t
Obesity  is characterized  by  a pro-inﬂammatory  state  commonly  associated  with  type  2 diabetes  and  fat-
liver disease.  In  the  last  few  years,  different  studies  pointed  out  the  role of  Angiotensin  (Ang)-(1–7)  in
the  metabolic  regulation.  The  aim  of the  present  study  was  to  evaluate  the  effect of oral-administration
of  Ang-(1–7)  in metabolism  and  inﬂammatory  state  of  high-fat  feed  rats. Twenty-four  male  Sprague
Dawley  rats  were  randomized  into  three  groups:  High  Fat  Diet (HFD);  Standard  Diet (ST); High  Fat
Diet  + Angiotensin-(1–7)  [HFD  + Ang-(1–7)].  Glycemic  proﬁle  was  evaluated  by  glucose  tolerance  and
insulin  sensitivity  tests,  plasmatic  glucose  and  insulin.  Cholesterol,  HDL and triglycerides  analyses  pre-
sented  lipidic  proﬁle.  RT-PCR  evaluated  mRNA  expression  to ACE,  ACE2,  resistin,  TLR4,  IL-6,  TNF-  and
NF-B  genes.  The  main  results  showed  that  oral  Ang-(1–7)  decreased  body  weight  and  abdominal  fat-
mass.  In addition,  HFD  + Ang-(1–7)  treated  rats  presented  enhanced  glucose  tolerance,  insulin-sensitivity
and  decreased  plasma-insulin  levels,  as well  as  a signiﬁcant  decrease  in  circulating  lipid levels.  These  alter-
ations  were  accompanied  by  a marked  decreased  expression  of resistin,  TLR4,  ACE and increased  ACE2
expression  in  liver.  Furthermore,  Ang-(1–7)  decreases  phosphorylation  of  MAPK  and increases  NF-B
expression.  These  alterations  diminished  expression  of  interleukin-6  and  TNF-,  ameliorate  inﬂamma-
tory  state  in liver.  In  summary,  the  present  study  showed  that oral-treatment  with  Ang-(1–7)  in high-fat
feed  rats  improved  metabolism  down-regulating  resistin/TLR4/NF-B-pathway.. Introduction
Obesity is characterized by an increase in white adipose tissue
ass, which can result from an excess of food (energy) intake
r altered energy expenditure [5]. Obesity has been recently
escribed as a systemic and local adipose proinﬂammatory state,
nd this has been implicated in the development of medically
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important complications, including hepatic steatosis, insulin
resistance, and atherosclerosis [16,23,30]. Classic markers of the
obesity-induced inﬂammatory state include the augmented tissue
and circulating levels of proinﬂammatory enzymes, procoagulant
factors, cytokines, and chemokines [6,30].
Among these adipokines, resistin is described as a potential
factor in obesity-mediated insulin resistance, type 2 diabetes
and inﬂammation [13]. Resistin is a cysteine-rich polypeptide
secreted by adipose tissue in rodents and by macrophages in
humans, promoting inﬂammation by regulation of the synthesis
and secretion of key proinﬂammatory cytokines such as tumor
necrosis factor- (TNF-),  interleukin-6 (IL-6) in macrophages via
a nuclear factor-kappaB-dependent (NF-B) [24]. Moreover, recent
study has provided for the contribution of Toll-like receptor-4
(TLR4) in the pathogenesis of obesity and inﬂammation [28].
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n a human epithelial cell line in which resistin competes with
ipopolysaccharide (LPS) for binding to TLR4 [27].
The renin–angiotensin system (RAS) is now recognized to be
mportant for the development of cardiovascular and metabolic dis-
rders [18,20,21]. Angiotensin II (Ang II), a major effector of RAS, is
nown as a vasoconstrictor, however, recent study has shown its
ole as a potent mediator in the activation of inﬂammatory mech-
nisms involved in obesity [3,26]. On the other hand, angiotensin
onverting enzyme 2 (ACE2)/Angiotensin-(1–7) (Ang-(1–7))/Mas
xis has been suggested as an important counterregulatory arm in
he RAS with effects opposite to those of ACE/Ang II/AT1 [18,19].
ng-(1–7) exerts an important role of antiobesity by Mas  receptor
18–21].
The pharmacological potential of Ang-(1–7) was  signiﬁcantly
ncreased after the development of a new oral formulation
haracterized by a protected Ang-(1–7) molecule included in
cyclic-oligosaccharides (cyclodextrin). This novel compound
as denominated [hydroxypropyl--cyclodextrin/Ang-
1–7) − HPCD/Ang-(1–7)] [12]. It has been described that
ng-(1–7) included into this HPCD cavity, can be protected
uring the passage through the gastrointestinal tract after oral
dministration [4].
In this context, the aim of the present study was  to evaluate the
ffect of an oral formulation of Ang-(1–7) in diet-induced obesity,
etabolic regulation and in resistin liver signaling pathway, which
s involved in the inﬂammation responsiveness.
. Methods and materials
.1. Animals
Twenty-four male Sprague Dawley rats from Federal Univer-
ity of the Minas Gerais (Belo Horizonte, Minas Gerais, Brazil) were
ivided into three groups (n = 8) and fed respective experimen-
al diets for 8 weeks: High Fat Diet (HFD), Standard Diet + HPCD
ST); High Fat Diet + Ang-(1–7) included in HPCD [HFD + Ang-
1–7)] − 100 g/kg body weight (dose were corrected ever week
ccording with body weight).
.2. Diets
The animals fed with Standard Diet (Purina – Labina®) used for
egular maintenance of our rats is composed of 50.30% of carbo-
ydrate, 41.90% of protein and 7.80% of fat presenting a total of
.18 kcal per 1 g of diet. High-fat diet was composed of 24.55% of
arbohydrate, 14.47% of protein and 60.98% of fat, presenting a total
f 5.28 kcal per 1 g of diet [2].
.3. Measurements of body weight, food intake and tissue
ollection
The food intake was measured twice a week during the treat-
ent to obtain food efﬁciency (food intake/body weight). Overnight
asted rats were killed by decapitation and samples of blood and
pididymal, retroperitoneal white adipose tissue and liver were
ollected, weighed and immediately frozen in dry ice and stored
t −80 ◦C for subsequent analysis.
.4. Glucose tolerance and insulin sensitivity tests
For the glucose tolerance test, d-glucose (2 mg/g body weight)
as intraperitoneally injected into overnight fasted rats. Glucose
evels from tail blood samples were monitored at 0, 15, 30, 60, and
20 min. An insulin sensitivity test was performed on overnight-fed
ats, after intraperitoneal injection of insulin (0.75 units/kg bodyes 46 (2013) 47–52
weight). Tail blood samples were taken at time 0, 15, 30, and 60 min
after injection.
2.5. Determination of plasma parameters
Total serum cholesterol, high-density lipoprotein (HDL), trigly-
cerides were assayed using enzymatic kits (Doles®, Goiania, Brazil).
Enzyme-linked immunosorbent assay kits were used to measure
serum adiponectin and insulin (Adipo-Gen®, Seoul, Korea) and lep-
tin (Lincoln®, St. Louis, USA) levels.
2.6. Reverse transcription and qRT-PCR
Total RNA from the liver was  prepared using TRIzol reagent
(Invitrogen Corp.®, San Diego, California, USA), treated with DNAse
and reverse transcribed with M-MLV  (Invitrogen Corp.®) using
random hexamer primers. The endogenous glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), ACE, ACE2, resistin, TLR4, IL-6,
TNF- and NF-B cDNA were ampliﬁed using speciﬁc primers and
SYBR green reagent (Appllied Biosystems®, USA) in an PlusOne
platform (Appllied Biosystems®). Relative comparative CT method
was applied to compare gene expression levels between groups,
using the equation 2−CT [11].
2.7. Western blot analysis
Proteins were extracted from epididymal adipose tissue sam-
ples of rats and 30 g of protein were resolved on SDS–PAGE
gels (10%), transferred onto nitrocellulose membranes and blocked
with Odyssey Blocking Buffer 1× (LI-COR Biosciences®, Germany).
For immunoblotting, the membranes were probed with a poly-
clonal rabbit anti-p38/MAPK (Thr180/Tyr182) antibody (1:1000;
Cell Signaling Inc., USA). The blots were then incubated with -
actin anti-rabbit IgG (1:1000; Sigma–Aldrich, Germany), was used
as endogenous control. The blots were viewed using an infrared
Q3127 LICOR® scanner and analyzed using the Odyssey® software.
The results were expressed by the relationship antibody primary/-
actin in units of relative density.
2.8. Statistical analysis
Data are expressed as the mean ± SEM. The statistical signif-
icance of differences in mean values between rats groups was
assessed by one-way ANOVA or 2-way ANOVA (glucose tolerance
and insulin sensitivity tests) and the Bonferroni post test. Signiﬁ-
cance level was set at P < 0.05.
3. Results
Oral administration of Ang-(1–7) decreased body weight in
HFD + Ang-(1–7) rats when compared with HFD during the period
of treatment. At the end of the experiment the body weight was
351.7 ± 17.51 g, 405.0 ± 36.99, and 367.0 ± 35.29 g in ST, HFD and
HFD + Ang-(1–7), respectively (Fig. 1A). We did not observe signif-
icant alteration between groups when evaluating food efﬁciency
(food intake/body weight) (Fig. 1B).
Analysis of epididymal (ST: 0.0129 ± 0.0039 g/g BW;  HFD:
0.0198 ± 0.0031; HFD + Ang-(1–7): 0.0151 ± 0.0034) and retroperi-
toneal adipose tissues (ST: 0.0098 ± 0.00028 g/g BW;  HFD:
0.021 ± 0.0038; HFD + Ang-(1–7): 0.0153 ± 0.0041) demonstrated
a reduced fat composition in HFD + Ang-(1–7) (Fig. 1C and D).
Additionally, total liver weight g/g BW did not display differences
between groups (Fig. 1E).
HFD + Ang-(1–7) rats presented a signiﬁcant decreased in
total cholesterol (ST: 21.62 ± 3.97; HFD: 25.83 ± 3.74; HFD + Ang-
(1–7): 20.74 ± 2.72) and triglycerides (ST: 67.88 ± 14.93; HFD:
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Fig. 1. Body weight, food intake, and lipidic and glycemic proﬁle of ST, HFD and HFD + Ang. (A) Body weight (g) of 8-week-old ST, HFD and HFD + Ang-(1–7) (n = 8) male rats. In
HFD  was  signiﬁcantly increased (*P < 0.05) in comparison to ST and HFD + Ang-(1–7). (B) Food intake, there was no signiﬁcant difference between the groups. (C) Epididymal
adipose tissue weight was signiﬁcantly increased (*P < 0.05) in comparison to ST and HFD + Ang-(1–7). (D) Retroperitoneal adipose tissue weight was signiﬁcantly increased
(***P  < 0.001) in comparison to ST and (**P < 0.01) in comparison to HFD + Ang-(1–7). (E) Liver weight had no signiﬁcant difference between the groups. Serum levels of total
cholesterol. (F) Serum levels of triglycerides. (G) Serum levels of high-density protein. (H) Glucose tolerance test. Overnight-fasted mice were given an intraperitoneal injection
of  glucose (2 mg/g body weight). Data are presented as mean of plasma glucose levels (mg/dl) ± SE from six rats in each group. (I) Insulin sensitivity test after intraperitoneal
injection of insulin (0.75 units/kg body weight). Blood samples were collected from the tail at indicated time points and analyzed for glucose concentration. Results are













(5.97 ± 15.83; HFD + Ang-(1–7): 54.29 ± 4.82) in relation to the
FD group (Fig. 1F and G). Serum levels showed no differences in
DL between groups (Fig. 1H).
A low glucose tolerance and decreased insulin sensitivity
ere observed in HFD rats when compared with HFD + Ang-
1–7) (Fig. 1I and J). This state was accompanied by a decrease
n fasting plasma glucose levels and plasmatic insulin (Fig. 1K
nd L).
Levels of resistin were signiﬁcantly higher in HFD rats
ST: 0.79 ± 0.11; HFD: 1.08 ± 0.16; HFD + Ang-(1–7): 0.63 ± 0.18)
Fig. 2A). Additionally, we examined the effect of Ang-(1–7) treat-
ent on TLR4 expression. Our data showed that HFD + Ang-(1–7)
ats markedly decreased the mRNA expression of TLR4 in the liver
Fig. 2B).To investigate the potential link between resistin and proin-
ﬂammatory pathways, we studied the impact of oral of Ang-(1–7)
treatment in rats on the phosphorylation of mitogen-activated
protein kinase (MAPK), levels of resistin/TLR4-signaling compo-
nents and proinﬂammatory cytokines in the livers of these animals.
HFD + Ang-(1–7) group showed decreased total and phosphoryla-
tion MAPK expression as compared with the HFD group (Fig. 2C and
D). Additionally, this study revealed increased ACE2 and decreased
ACE expression (Fig. 2E and F). We  did not observe signiﬁcant alter-
ation between groups when evaluating Mas  receptor expression
(Fig. 2G).
The mRNA expression of proinﬂammatory cytokines by q RT-
PCR in the liver showed a signiﬁcant decrease of NF-B, TNF- and
IL-6 in HFD + Ang-(1–7) group (Fig. 3A and C). The expression of the
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Fig. 2. Liver mRNA expression performed by qRT-PCR and western blotting analyses. (A) mRNA expression of resistin. (B) mRNA expression of TLR4. (C) Western blot for total
M sphor

























AAPK  protein. Illustrative picture of western blotting gel. (D) Western blot for pho
ith  primary and secondary antibodies for p38/MAPK detection, the membrane w
E)  Expression of ACE2. (F) Expression of ACE. (G) Expression of Mas  receptor. *P < 0
L-1 did not differ among the groups (Fig. 3D). Fig. 3E illustrates
ignaling mechanism involved Resistin/TLR4/MAPK/NF-B.
. Discussion
Obesity is a pernicious public health problem commonly asso-
iated with type 2 diabetes and insulin resistance state. Recent
tudies linked different obesity complications and insulin resis-
ance state with high resistin levels [13]. Resistin is an important
dipokine that is positively correlated with high-fat mass and
as been associated with a proinﬂammatory state as reported in
hronic liver diseases [16]. Resistin also modulates the synthesis
nd secretion of key proinﬂammatory cytokines such as TNF- and
L-6 through a NF-B-dependent pathway [17]. Despite of several
ecent studies describing resistin pathophysiology, only a small
art of resisitin signaling is known and its importance in inﬂam-
ation process has just started to be investigated. In the present
tudy we evaluated for the ﬁrst time the effects of oral Angiotensin-
1–7) administration in the inhibition of the inﬂammatory pathway
 resistin/TLR4/MAPK/NF-B  in the liver of obese rats.
Recent studies demonstrated the beneﬁt of metabolic effects of
he Ang-(1–7)/Mas axis activation [2,19–21]. In the present study
e mainly observed that oral formulation of Ang-(1–7) produced
n important reduction in body weight and adipose tissue mass
ssociated with decreased serum total cholesterol and triglycerides
evels followed by ameliorated insulin sensitivity, glucose tolerance
nd diminished expression of proinﬂammatory cytokine mRNAs.
dditionally, we showed a decrease in TLR4 and MAPK expressionylated MAPK protein. Illustrative picture of western blotting gel. After incubation
pped and incubated with primary and secondary antibody used to detect -actin.
d **P < 0.01 in comparison to the HFD group.
in the liver associated with decreased ACE and increased ACE2
expression.
Liver is a complex and important organ and plays an essen-
tial role on lipid and glucose metabolic regulation. Several studies
showed that many RAS components are expressed in the liver med-
dling metabolic and inﬂammatory processes [2,29]. The increased
expression of Ang II induced non-alcoholic fatty liver disease and
modulates inﬂammatory cell recruitment into the liver during
liver injury [8,29]. Additionally, it was  previously demonstrated
that ACE2/Ang-(1–7)/Mas axis expression is down-regulated dur-
ing obesity [20,21]. Rats with increased Ang-(1–7) levels had lower
body weight and decreased IL-1 and COX-2 in adipose tissue asso-
ciated with improved liver glucose metabolism [2]. Our results are
in agreement with these data showing an elevated expression of
ACE2 and decreased ACE in the livers of HFD + Ang-(1–7) treated
rats.
It has been shown that lipid and glycemic parameters can
be modulated by resistin expression. [22], especially considering
that resistin is produced by adipocytes, which are augmented in
obese liver. Kushiyama et al. showed that resistin-like molecule
beta activates MAPKs, suppresses insulin signaling in hepatocytes
and induces diabetes, hyperlipidemia and fatty liver in transgenic
mice on a high fat diet model [9]. Our results indicate that obese
rats with increased liver resistin expression exhibit an insulin-
resistant state, glucose intolerance, hyperinsulinemia and altered
lipid metabolism. Furthermore, we showed that rats treated with
Ang-(1–7) presented with diminished liver resistin expression
associated with increased ACE2 expression. These results are in
agreement with the data obtained in previous studies [9,10].
S.H.S. Santos et al. / Peptides 46 (2013) 47–52 51






























if  Ang-(1–7)/resistin/TLR4/MAPK/NF-B signaling-pathway. Data are presented a
P  < 0.05 and **P < 0.01 in comparison to the HFD group.
Oh et al. recently showed that captopril (ACE inhibitor) intake
ecreases body weight gain via Angiotensin-(1–7) [14]. This
lteration was associated with Mas  receptor mRNA increased
xpression [14]. Additionally, a previous study with DOCA
alt-induced hypertension transgenic rats, that presents an overex-
ression of Ang-(1–7) in the circulation, also showed an increase in
eart Ang-(1–7) accompanied by a decrease in ACE mRNA expres-
ion [17]. These data support our hypothesis of a modulatory role
or Ang-(1–7) in the ACE/ACE2 ratio. Another possibility is that
he improved metabolic proﬁle by itself, with lower lipid content
nd enhanced glucose metabolism, was able to increase ACE2 and
ecrease ACE expression.
A previous report revealed that Ang II treatment increases
dipocytes secretion of resistin [7]. Resistin has been also asso-
iated with the inﬂammatory state of chronic liver disease [25]
nd modulates the synthesis and secretion of key proinﬂammatory
ytokines such as TNF- and IL-6 [24]. The molecular mechanisms
nvolved in the inﬂammatory response of resistin are still unclear,
owever a recent report indicated that resistin could compete with
PS for TLR4 [9]. Additionally a recent investigation reported the
ontribution of central resistin overexposure to induction of insulin
esistance through TLR4 and activation of MAPK pathway [1]. In
ur study, we showed decreased TLR4 mRNA expression in liver
f HFD + Ang-(1–7) rats associated with low phosphorylation of
APK. This fact is important once resistin-TLR4 signaling in the
ypothalamus leads to the activation of MAPK pathway promoting
verall inﬂammation [1].It is known that MAPK activation initiates the downstream
nduction of transcription factors such as NF-B, which is an
ssential regulator of the expression of numerous genes involved
n the function and development of the immune system and inns ± SE. Statistically signiﬁcant differences between the groups are indicated as
inﬂammatory responses [22]. Activated NF-B is the major regula-
tor, facilitating the synthesis of several different injury-responsive
cytokines in neurons, adipose tissue and liver [2,22,24]. Previous
studies showed an elevated level of NF-B in the adipose tissue of
rats with increased levels of resistin [15,25]. In this study, oral treat-
ment with Ang-(1–7) reduced TNF- and IL-6 through inhibition of
NF-B.
5. Conclusion
In summary the present study showed that Ang-(1–7) oral treat-
ment in rats fed high-fat feed prevent obesity and the decrease
of several liver proinﬂammatory cytokines by down-regulating
the resistin/TLR4/NF-B  pathway. Thus, our ﬁndings suggest that
ACE2/Ang-(1–7)/Mas axis might be a novel therapeutic agent for
the prevention and treatment of obesity-related liver disorders.
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